Zimmer Biomet Holdings (ZBH) just delivered Q3 2026 results that topped revenue and adjusted EPS expectations, and management responded by lifting full year sales growth and earnings guidance, putting fresh focus on the stock.
The market reaction has been swift. Zimmer Biomet Holdings has a 1-day share price return of 13.49% and a 7-day share price return of 14.28%, lifting the year-to-date share price return to 22.36% and contributing to a 27.16% 1-year total shareholder return. This points to momentum building as investors reassess both growth prospects and risk after the updated guidance.
Scan how Zimmer Biomet Holdings fits alongside other medical technology players delivering strong segment performance and guidance upgrades by reviewing our hand-picked 38 healthcare AI stocks in this space.
Zimmer Biomet Holdings just reminded investors it runs a sizeable, long-lived orthopedics franchise with growing tech and data arms. After a double digit jump in the share price, is that quality now fairly valued or overpaid for?
Most Popular Narrative: 2% Overvalued
Zimmer Biomet Holdings closed at $110.15 against a widely followed fair value estimate of $107.57. The narrative currently prices the shares as slightly rich while still grounded in detailed margin and growth assumptions.
The current valuation implies that the market is not fully crediting Zimmer Biomet for raised 2026 growth and EPS guidance, stronger free cash flow, and higher planned share repurchases. Taken together, these factors suggest a more optimistic view of the share price than is currently reflected.
See why 38 investors see Zimmer Biomet Holdings as 2% overvalued .
Result: Fair Value of $107.57 (OVERVALUED)
Still, pressure on adjusted gross and operating margins, along with execution risk around manufacturing changes and Project Optima, could easily challenge that slightly overvalued Zimmer Biomet narrative.
Find out about the key risks to this Zimmer Biomet Holdings narrative .
Another View: Zimmer Biomet Through A Cash Flow Lens
The fair value narrative pegs Zimmer Biomet Holdings at $107.57 and slightly overvalued on that basis. A different lens tells another story. The Simply Wall St DCF model estimates the future cash flow value at $260.92 per share, which frames the current $110.15 price as significantly undervalued instead. Which signal do you trust more: the earnings based target or the long term cash flow math?
For a closer look at how that long range model is built and what assumptions sit underneath it, take a few minutes to walk through the Look into how the SWS DCF model arrives at its fair value. .
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Zimmer Biomet Holdings for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 34 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages around Zimmer Biomet Holdings valuation are clear, so move quickly, review the underlying metrics, compare the upside and downside, then weigh the 2 key rewards and 2 important warning signs .
Looking for more investment ideas beyond Zimmer Biomet Holdings?
If Zimmer Biomet Holdings has your attention after this update, do not stop here. Cast the net wider now and give yourself a stronger opportunity set for the next decision.
-
Target resilient balance sheets and steady fundamentals by scanning our list of solid balance sheet and fundamentals (25 results) that highlight businesses built to handle tougher conditions.
-
Hunt for quality at a discount and stress test your valuation thesis against our curated 34 high quality undervalued stocks designed for disciplined stock pickers.
-
Build a cash flow focused portfolio by reviewing the 5 dividend fortresses that put reliable income potential right next to key financial health checks.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZBH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
